TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Two Anesthetic Techniques in Magnetic Resonance Imaging (MRI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects presenting as out-patients, scheduled to receive an anesthetic for MRI of body (spine, chest, abdomen, and/or pelvis) and/or extremity (arm and/or leg).~2. The subject must be a candidate for both anesthetic techniques. This decision will be made by a staff member of the Department of Anesthesiology. This staff member will not be a member of the study team and will obtain the consent for Anesthesia.~3. The subjects must be 12 months to 7 years (inclusive of the seventh year).~4. The subject's legally authorized representative has given written informed consent to participate in the study.~Exclusion Criteria:~1. The subject is residing in the Pediatric Intensive Care Unit, the Cardiac Intensive Care Unit, or Neonatal Intensive Care Unit.~2. Anxiolytic medication is ordered before the MRI (e.g., midazolam or ketamine).~3. The subject has a history or a family (parent or sibling) history of malignant hyperthermia.~4. The subject has life-threatening, medical conditions (American Society of Anesthesiologists Physical Status 4, 5 or 6).~   * The American Society of Anesthesiologists (ASA) classification scale is a measure of physical status or how healthy the patient is.~  * For our study, we will focus on children which are defined as ASA I, II or III which means a healthy child (ASA I), a child with a systemic disease that is mild and well controlled (ASA II) or a child with systemic disease that is severe and controlled (ASA III).~5. The subject is allergic to or has a contraindication to any of the drugs used in the study.~6. The subject has previously been treated under this protocol.~7. The subject has a tracheostomy or other mechanical airway device.~8. The subject has received within the past 12 hours an oral or intravenous alpha-adrenergic, beta-adrenergic agonist, or antagonist drugs (e.g., clonidine, propranolol, albuterol).~9. The subject is not scheduled to receive anesthesia-sedation care for the MRI.~10. The subject received one of the anesthetic regimens for the same MRI during the past six months.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 7 Years
- Healthy Volunteers: t

Study Arms:
- dexmedetomidine (Type: ACTIVE_COMPARATOR): Determine if there is a significant difference in the quality of care between our two standard anesthesia techniques for children undergoing a MRI of the body and/or extremity MRI.
- propofol (Type: ACTIVE_COMPARATOR): Determine if there is a significant difference in the quality of care between our two standard anesthesia techniques for children undergoing a MRI of the body and/or extremity MRI.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Insulin Therapy for Post-transplant Glucocorticoid Induced Hyperglycemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Have undergone bone marrow, liver, lung, or renal transplant.~2. Be using once daily oral glucocorticoid therapy (total daily dose of Prednisone ≥10 mg, Hydrocortisone ≥40 mg, Dexamethasone ≥1.5 mg) administered in the morning and expected to continue for at least 2 weeks.~3. Have pre-existing or newly diagnosed diabetes mellitus established by any of the criteria listed below:~   1. Fasting plasma glucose ≥7.0 mmol/L (repeated x 1)~  2. Any plasma glucose ≥11.0 mmol/L~4. Have at least three pre-meal inpatient capillary blood glucose (CBG) readings ≥ 7.8 mmol/L~5. Be eating meals by mouth~Exclusion Criteria:~1. Heart, Pancreas, Islet cell transplant recipients~2. Previous use of Basal-Bolus or Pre-Mixed Insulin regimen~3. Diabetes mellitus type I~4. NPO (not eating meals by mouth)~5. Receiving enteral (tube feeds) or parenteral (TPN) nutrition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Neutral protamine hagedorn (NPH) insulin (Type: ACTIVE_COMPARATOR): Drug: Neutral protamine hagedorn (NPH) insulin~Other Names:~Humulin N, Novolin N~Route: Subcutaneous; Dosage: No fixed dose, varies between subjects; Frequency: daily before breakfast; Duration: 12 hours; for duration subjects are concurrently administered once-daily glucocorticoid.
- Regular or Aspart insulin (Type: EXPERIMENTAL): Drug: Regular human insulin or Insulin Aspart~Other Names:~Humulin R, Novolin R, Novolog, NovoRapid~Route: Subcutaneous; Dosage: No fixed dose, varies between subjects; Frequency: daily before meals; Duration: 2 hours (Aspart) or 6 hours (Regular); for duration subjects are concurrently administered once-daily glucocorticoid.
- Insulin glargine (Type: EXPERIMENTAL): Drug: Insulin glargine~Other Names:~Lantus~Route: Subcutaneous; Dosage: No fixed dose, varies between subjects; Frequency: daily before breakfast; Duration: 24 hours; for duration subjects are concurrently administered once-daily glucocorticoid.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically confirmed CLL or SLL requiring therapy~* Age 18 years of age or older~* ECOG performance status 0, 1, or 2~* Normal organ and bone marrow function~* Resolution of toxic effects from prior therapies~* Ability to adhere to the study schedule and give written informed consent~Exclusion Criteria:~* Any serious medical, psychiatric illness or laboratory abnormality~* Chemotherapy or radiotherapy within 4 weeks of entering the study~* Currently receiving other treatment for CLL/SLL or other malignancies~* Active other malignancies~* History of allergic reactions to bendamustine or ofatumumab~* Ongoing corticosteroid use~* Pregnant or lactating~* HIV positive~* Active hepatitis B~* Allogeneic transplant within 6 months of entering study or graft-versus-host disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ofatumumab and Bendamustine (Type: EXPERIMENTAL): Ofatumumab and Bendamustine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI and Rational Dose Selection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have histologically or cytologically confirmed malignancy (not leukemia or lymphoma). There must be metastatic brain disease apparent on magnetic resonance imaging which offers a medical indication for brain radiation. - Age \> 18~* Karnofsky Performance Status \> 70~* MRI performed within 4 weeks of trial enrollment~* Medical oncologist or consenting physician verifies that chemotherapy options exist after treatment with intracranial therapy, and that chemotherapy is planned to initiate after completion of radiation. Or, survival as estimated by the medical oncologist or enrolling physician is \> 3 months.~Exclusion Criteria:~* Extremely radiosensitive tumor (lymphoma, leukemia)~* Radiosensitivity syndrome (scleroderma, dermatomyositis, other genetic syndrome that predisposes to adverse radiotherapy complications)~* Evidence of leptomeningeal dissemination~* Resection of brain metastases, otherwise untreated with radiation for those brain lesions (presenting for postoperative consolidative radiotherapy)~* Presence of a medical device (pacemaker, stent) or allergy that precludes contrast enhanced MRI~* Patient is unable to tolerate placement of a stereotactic headframe~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gamma Knife Radiosurgery (Type: EXPERIMENTAL): Rational dose selection is a concept wherein doses used for stereotactic radiosurgery is selected based on tumor volume, prior irradiation with whole brain radiotherapy, and the relative radioresistance of the tumor (radioresistant = melanoma, renal cell carcinoma, sarcoma; radiosensitive = breast cancer, lung cancer, colorectal cancer, gastrointestinal cancers).~Dose may be altered for lesions in the brainstem, adjacent to the optic nerve, optic chiasm, or motor cortex, or other clinical scenarios as defined by the treating physician. Reason for dose alteration will be recorded at the time of treatment.~For patients with 10+ brain metastases with multimorbidity or difficulty in tolerating a supine position, doses may be modified by the treating physicians for patient comfort.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Secondary Prevention of Atrial Fibrillation (Impact of Renin-Angiotensin-Aldosterone System Inhibition)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be in atrial fibrillation confirmed by 12 lead EKG.~* blood pressure \> 90 mmHg~* Patient without cardiopulmonary symptoms~* 18+ years of age~Exclusion Criteria:~* Contraindiction to warfarin~* Recent (within 6 months) MI or cardiac revascularization~* Recent (within 6 months) CVA or TIA~* NYHA Class IV CHF~* Active thyroid disease~* Major hepatic dysfunction~* Renal dysfunction (\>2 mg/dL)~* Hyperkalemia (\>4.6 mEq/L)~* Hyponatremia (\<130 mEq/L)~* Currently taking a Vaughn-Williams Type I or III antiarrhythmic drug~* History of ARB intolerance~* Contraindication to ARB therapy~* Pregnancy~* Female of childbearing age~* Age \< 18 years of age~* Inability to give informed consent~* Other medical conditions calling 1 year survival into question

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A Group 1 no drug (Type: EXPERIMENTAL): Patients who have not taken ACE/ARB, randomized to no drug.
- A Group 2 (Type: EXPERIMENTAL): Patients who have not taken ACE/ARB, randomized to take cozaar.
- B (Type: EXPERIMENTAL): Patients currently taking ACE/ARB will have their prescription changed to cozaar.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Vinorelbine and Oxaliplatin (Vinox) With or Without Trastuzumab (Herceptin®) in Advanced Breast Carcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Metastatic, histologically or cytologically proven breast cancer.~* At least one bi-dimensionally measurable lesion.~* Previous treatment with chemotherapy as first line for metastatic disease is mandatory especially with anthracyclines +/- the Taxanes.~* Treatment as adjuvant is allowed.~* World Health Organization-ECOG performance status 0-2.~* Adequate renal function (Creatinine \<= 1.4 or Creatinine clearance \>= 30 ml/min)~* Adequate hepatic function (Liver Function Tests not more than 3 times the normal values)~* Adequate bone marrow reserve is required (Neutrophils (PMN) \>= 2000/mm2 and Platelets \>= 100,000/mm2)~* Patient who will receive Herceptin should have an over-expression of HER2-neu.~Exclusion Criteria:~* Symptomatic peripheral neuropathy (National Cancer Institute common toxicity criteria grade more than one).~* Pregnant or breast-feeding.~* History of prior malignancies (with the exception of excised cervical carcinoma-in-situ or non-melanoma cell skin carcinoma).~* Receiving or had received, any treatment with experimental drugs.~* Had known brain or leptomeningeal involvement.~* Had a serious medical condition like congestive heart failure or an Ejection Fraction ≥ 40 %.~* The presence of bone as a sole site of metastasis.~* Radiation therapy to all areas of measurable disease less than four weeks before treatment.~* Creatinine two times above the normal range~* Hypercalcemia~* Evaluable but not a measurable disease as a sole site of metastasis: pleural effusion - Ascites - Pericardial effusion.~* Concomitant steroid intake for \> 4 weeks~* Bilirubin two times above the normal range~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Correlation Between Sagittal Balance of the Spine and Psychopathological Profile

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Men and women aged 18 to 70 years ·~* Spine surgery outpatients with or without low back pain with radicular ·- Affiliated to a social security scheme,~* Having signed an informed consent and were informed of the results of the consultation prior to inclusion~Exclusion Criteria:~* Patients having the major diseases of the spine: deformities (scoliosis, kyphosis), tumors, fractures, inflammatory and metabolic ·~* Patients having a spinal surgery history ·~* Patients difficult to inform ( emergency ward patients, patients with difficulties in oral comprehension)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Diagnostic Performance of Dual Energy CT for the Detection of Gallbladder Gallstones

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patient referred to the radiology department for an abdominal CT for abdominal pain, suspicion of cholangitis, cholecystitis, migration of stones, acute pancreatitis, suspicion of perforated ulcer in the emergency setting.~* Non-objection of the subject to participate in the study~* Affiliation to a French social security scheme or beneficiary of such a scheme.~Exclusion Criteria:~* Cholecystectomy~* Legal incapacity or limited legal capacity, legal safeguard~* Pregnant women~* Subject unlikely to cooperate in the study and/or low cooperation anticipated by the investigator~* Subject being in the exclusion period of another study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- gallblader ultrasound (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: N-Acetylcysteine Augmentation in Treatment-Refractory Obsessive-Compulsive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* DSM-IV diagnosis of OCD, confirmed by SCID-IV; symptoms of at least 1 year duration~* moderate to severe OCD symptoms (Y-BOCS \> 16)~* documented failure of an adequate trial of an SSRI~* agreement to engage in a reliable form of birth control (women only)~Exclusion Criteria:~* primary diagnosis of a psychotic disorder~* active substance abuse or dependence~* unstable medical condition~* prior exposure to N-Acetylcysteine~* prior psychosurgery~* pregnancy, breastfeeding, or intent to become pregnant during study~* liver function tests (LFTs) elevated to more than 2x the upper limit of normal~* evidence of active liver disease~* seizure disorder~* active suicidal ideation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- N-Acetylcysteine (Type: EXPERIMENTAL): Patients randomized to this arm will receive N-Acetylcysteine augmentation, at a standard dose titrated to 3000 mg within the first week, in addition to the medication regimen they are on at enrollment
- placebo (Type: PLACEBO_COMPARATOR): Patients randomized to this arm will receive placebo, formulated to be indistinguishable from N-Acetylcysteine, in addition to the medication regimen they are on at study enrollment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with SLE meeting the 1997 ACR Classification Criteria~* Evidence of positive ANA or anti-dsDNA within one year of screening~* SLEDAI ≥4 or ≥1 BILAG A or B at screening, despite standard of care~Exclusion Criteria:~* Leukopenia (WBC \<2.000/mm3) or lymphopenia (lymphocytes \< 300/mm3)~* AST or ALT \>3 times above normal cut off values~* Acute lupus nephritis defined as class II, IV or V nephritis diagnosed within 6 months or prot/creat \> 1.5 gm/gm due to active lupus or in process of receiving induction therapy for nephritis~* Active CNS lupus affecting mental status~* Pregnancy or breast feeding~* Current requirement for anticoagulation~* Contraindication to aspirin or dipyridamole, including history of recent or severe GI bleeding, hemoglobin \<9 mg/dL, platelet count of \<30,000 /mm3 or unstable platelet count~* Any other medical condition, whether or not related to lupus which, in the opinion of the investigator would render the patient inappropriate or too unstable to complete the study protocol~* Inability or unwillingness to understand and/or sign informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- extended release dipyridamole/aspirin (Type: EXPERIMENTAL): extended release dipyridamole 200mg/aspirin 25mg twice daily for 24 weeks
- aspirin (Type: ACTIVE_COMPARATOR): half a tablet of a 81mg aspirin twice daily for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have atopic dermatitis (AD) for at least 1 year (365 days) prior to the first administration of study intervention as determined by the investigator through participant interview and/or review of the medical history~* Have a history of inadequate response to treatment for AD with topical medications or for whom topical treatments are otherwise medically inadvisable (example, due to important side effects or safety risks)~* Have an Eczema Area and Severity Index (EASI) score greater than or equal to (\>=) 16 at screening and at baseline~* Must sign an informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study~* Must be willing to undergo 4 skin biopsies~* Have an Investigator Global Assessment (IGA) score \>=3 at screening and at baseline~* Have an involved body surface area (BSA) \>=10 percent (%) at screening and at baseline~Exclusion Criteria:~* Has a current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances~* Has ever received any Human interleukin-1 (IL-1) antagonist (example, including but not limited to anakinra, rilonacept)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Part A: Bermekimab Dose 1 (Type: EXPERIMENTAL): Participants will receive bermekimab Dose 1 or placebo as an intravenous (IV) infusion weekly from Week 0 to Week 15.
- Part B: Bermekimab Dose 2 (Type: EXPERIMENTAL): Participants will receive bermekimab Dose 2 or placebo as an IV infusion weekly from Week 0 to Week 15.
- Part C: Bermekimab Dose 3 (Type: EXPERIMENTAL): Participants will receive bermekimab or placebo at a higher or lower dose (not less than \[\<\] Dose 1) than Part B, but with a maximum dose of Dose 3 IV weekly based on pharmacokinetic (PK), pharmacodynamic (PD), efficacy, and safety analysis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy